3Simpson GM. The treatment of tardive dyskinesia and dystonia. J Clin Psychiatry, 2000, 16(supple 4) : 39.
4Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underling the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav, 1994, 49(3) :663.
5Glazer WM. Expected incidence of tardive dyskinesia associated with atypicalantipsychotics. J Clin Psychiatry, 2000, 61(supple 4): 21.
6Barwick VS, Jones DH, Richter JT, et al. Subthalamic nucleus microinjections of 5-HT2 receptor antagonists suppress stereotypy in rats. Neumreport, 2000, 11(2):267.
7Warren JT, Peacock ML, Rodriguez LC, et al. An MspI polymorphism in the human semtonin receptor gene ( HTR2 ) : detection by DGGE and RFLP analysis. Hum Mol Genet, 1993, 2(3) : 338.
8Zhang HY, Ishigaki T, Tani k, et al. Serotonin receptor gene polymorphism inmood disorders. Biol Psychiatry, 1997, 41(7): 768.
9Williams J, Spurlock G McGuffin P, et al. Association between the 5-HT 2a receptor T102C polymorphism and schizophrenia. European Multicentre association Study of schizophrenia (EMASS Group). Lancet, 1996,347(9011): 1294.
10Arranz M J, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response, l~ncet, 2000, 355(9215) : 1615.
